安芙斯特制药（Amphastar Pharmaceuticals，股票代码：AMPH）今日盘中大涨5.41%，引起投资者广泛关注。这一显著涨幅主要源于公司发布的最新季度财报超出市场预期。
根据公司公布的财报，截至6月30日的季度调整后每股收益达到85美分，大幅超过分析师平均预期的74美分。尽管该数字低于去年同期的94美分，但仍然显著高于华尔街61美分至82美分的预期范围。公司季度营收为1.7441亿美元，虽同比下降4.4%，但仍略高于分析师预期的1.7334亿美元。
值得注意的是，尽管安芙斯特制药今日股价强劲反弹，但公司股价今年累计仍下跌43.9%。分析师对公司保持乐观态度，目前平均评级为"买入"，12个月目标价中位数为32.50美元，较上一交易日收盘价21.62美元高出约33.5%。这表明分析师认为该股仍有较大上涨空间，投资者可能正重新评估公司的长期价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.